Product Code: 596200687
Market barriers boost net share for 6 major RCC treatments in US. Is your brand one of them?
We researched 9 renal cell carcinoma (RCC) treatments to see what happens to their share of the US market when oncologists can't prescribe freely. The result: 6 of those brands actually saw a net gain.
Is your brand one of them, or one of the 3 that are losing out?
You'll learn how market barriers affect share for 9 major treatments from Bayer/Amgen, BMS, Genentech, Pfizer, and Prometheus.
Plus you'll see which brands your brand is losing share to, which ones you're taking it from, and why-information you can use to compete more effectively.
Get Answers to Key Questions about RCC Drug Brands
- Afinitor (everolimus; Novartis): Does Afinitor lose more share to Avastin or Sutent?
- Avastin (bevacizumab; Genentech): Are doctors who don't prescribe either brand more likely to consider Avastin or Opdivo?
- Inlyta (axitinib; Pfizer): Which two barriers contribute equally to Inlyta's small net share loss?
- Nexavar (sorafenib; Bayer/Amgen): Does Nexavar gain more share when other brands are too expensive or when they're not reimbursable?
- Opdivo (nivolumab; BMS): Opdivo and Sutent are prescribed equally. Which one has the clear market share advantage?
- Proleukin (aldesleukin; Prometheus): Which three barriers do more doctors experience with Proleukin than any other brand?
- Sutent (sunitinib; Pfizer): Which two brands would threaten Sutent if market barriers were eliminated?
- Torisel (temsirolimus; Pfizer): Torisel sees a net gain against all but three brands. Which three?
- Votrient (pazopanib; Novartis): Only two market barriers contribute to Votrient's net share gain. What are they?
- Most brands benefit from barriers: Six of the nine surveyed brands saw a net share gain due to barriers. Only three saw a net loss.
- Eliminating barriers would shake up the market: Especially the top of the market, where one middle-ranked brand would move into the top 3, pushing a leading brand out.
- Barrier effect is brand-specific: Each barrier tends to affect one or two brands far more than the others.
- All brands are heavily prescribed: Although a majority of doctors prescribe all but one of the surveyed brands, two brands are more prescribed than any of the others.
- Clear market leaders: Two brands-one of them among the most prescribed-have a clear market share lead.
- Brand perception is good: With a few exceptions, most doctors are willing to consider prescribing the brands they don't currently prescribe.
- Cost barriers have the greatest impact: barriers related to pricing and formulary availability (which is often related) affect more prescriptions than any others.
- Barrier effect significant for “other” brands: Taken together, “other” brands have a greater market share than 7 of the surveyed brands, and see the third biggest net share gain.
Exploring Market Access Issues
Market Access Impact: psoriasis explores key issues affecting RCC drug manufacturers. You'll learn:
How barriers affect market access:
- What brands do doctors prescribe the most?
- How many prescriptions do barriers affect?
- Which barriers have the biggest effect?
How barriers affect your brand:
- How many doctors prescribe your brand? How many don't, but would consider it?
- Why don't doctors prescribe your brand? What do they prescribe instead?
- Which competing brands does your brand take market share from?
A Report Based on Expert Knowledge
We surveyed 100 medical oncologists in the US, chosen from the largest community of validated physicians in the world.
All respondents have:
- Been practicing for 2+ years
- Prescribed at least one of the listed products
- Seen at least 5 patients with melanoma in total in the last month
We conducted the survey between April 4th and 11th, 2016.